Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Prognostic Value of Her2neu and EGFR in Primary Ovarian High Grade Serous Carcinoma.

NCT04284631 is registered in ClinicalTrials.gov with Port Said University hospital as lead sponsor.

NCT NCT04284631
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04284631 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Prognostic Value of Her2neu and EGFR in Primary Ovarian High Grade Serous Carcinoma.
Lead sponsor
Port Said University hospital
Phase
Observational
Overall status
Completed
Start date
January 1, 2012
Completion date
December 30, 2019
Enrollment
54 (actual)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

ovarian cancer